We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Stem Cells Not Progenitors Can Trigger Skin Cancer Growth

By LabMedica International staff writers
Posted on 21 Jul 2016
Cancer researchers have discovered that stem cells can initiate development of malignant skin tumors, while progenitor cells are limited to triggering only benign growths.

A progenitor cell is similar to a stem cell, in that it has a tendency to differentiate into a specific type of cell, but is already more specific than a stem cell and is pushed to differentiate into its "target" cell. More...
The most important difference between stem cells and progenitor cells is that stem cells can replicate indefinitely, whereas progenitor cells can divide only a limited number of times.

Investigators at the Université Libre de Bruxelles (Belgium) and the University of Cambridge (United Kingdom) sought to identify the type of cells that initiated formation of basal cell carcinoma, the most common form of skin cancer. To this end they assessed the impact of oncogenic hedgehog signaling in distinct cell populations and their capacity to induce cancer growth.

They reported in the July 8, 2016, online edition of the journal Nature that in a transgenic mouse model system only stem cells, and not progenitors, were competent to initiate tumor formation upon oncogenic hedgehog signaling. Clones derived from stem cells were able to overcome apoptosis and continue to divide and proliferate unchecked, developing into basal cell carcinoma. In contrast, the growth of clones derived from progenitor cells was checked by increasing levels of apoptosis, leading to the formation of benign lesions.

"It is incredibly rare to identify a cancer cell of origin and until now no one has been able to track what happens on an individual level to these cells as they mutate and proliferate," said senior author Dr. Cédric Blanpain, a professor at the Université Libre de Bruxelles. "We now know that stem cells are the culprits: when an oncogene in a stem cell becomes active, it triggers a chain reaction of cell division and proliferation that overcomes the cell's safety mechanisms."

"While this has solved a long-standing scientific argument about which cell types can lead to invasive skin tumors, it is far more than just a piece of esoteric knowledge," said contributing author Dr. Benjamin Simons, professor of physics at the University of Cambridge. "It suggests to us that targeting the pathways used in regulating cell fate decisions - how stem cells choose between cell proliferation and differentiation - could be a more effective way of halting tumors in their tracks and lead to potential new therapies."

Related Links:
Université Libre de Bruxelles
University of Cambridge

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.